Radionuclide Therapy Tops AR-Pathway Inhibitor Switch for mCRPC

(MedPage Today) -- MADRID -- Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) doubled when patients received a radionuclide ligand targeting prostate-specific membrane antigen (PSMA) instead...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news